Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2012

View Archived Issues

New S1P1 receptor ligands presented by researchers at Allergan

Fixed-dose combination drug evaluated in seasonal allergic and chronic rhinitis

Preclinical and phase I results presented for MLN-4924

First-in-human data presented on PD-1-targeted cancer immunotherapy

Otsuka and Kyowa Hakko Kirin to form strategic alliance

FAS-specific antibody for arthritis shows promise in first clinical trial

Multiple early-stage trials of MLN-9708 presented

OSI Pharmaceuticals divulges novel focal adhesion kinase inhibitors

German company discloses new muteins of human lipocalin

Marshall Edwards changes name

Janssen completes acquisition

Somatuline approved in Japan

New agents for hypercholesterolemia designed in Japan

Gilead submits NDA to FDA for AIDS drug

Pfizer patents novel kynurenine aminotransferase II inhibitors

Scientists at Biomay report new hypoallergenic vaccines

Novel antiviral agents developed

GABA(A) receptor modulator improves sleep in human model of insomnia

Laurantis Pharma presents phase I data on eye drop therapy

GSK and Theravance report on phase III COPD trials

Affymetrix expands product portfolio with acquisition

Japanese phase I study of SO-1105 complete

Bristol-Myers Squibb plans acquisition

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.